June 19, 2012 06:08 ET

Tougher Reference Pricing Environment and Drug Price Freeze Through 2013 Expected to Drive Down European Healthcare Costs

ROCKVILLE, MD--(Marketwire - Jun 19, 2012) - has announced the addition of the new report "Drug Price Cuts in Top Five Countries of Europe - Tougher Reference Pricing Environment and Drug Price Freeze through 2013 Expected to Drive Down Healthcare Costs," to their collection of Pharmaceuticals market reports. For more information, visit

It provides a comprehensive overview of the healthcare systems as well as pricing in five European nations with a detailed analysis of the different regulatory mechanisms used in these countries. The report closely scrutinizes major changes in pricing for pharmaceuticals in these European nations in the recent past and their impact in the near future. The countries analyzed in the report are the UK, Germany, France, Spain and Italy.

GBI Research's analysis describes healthcare across the Five European nations, which is largely publicly financed and is provided by health insurance systems; hence, the European governments play a key role in providing healthcare for their citizens. Health is of high priority for Europe's citizens and pharmaceutical costs are the third most important component in the member states' healthcare budgets.

Currently, the governments of the member countries face substantially rising costs for the provision of health care (average costs are rising at a faster rate than GDP) due to over-prescription of drugs, their irrational usage, and other key factors such as Europe's ageing population and increasing cost of new medical technologies.

Consumer preference for branded drugs to generic drugs in cases where the patent for the drug has expired is also one of the reasons for increasing healthcare costs. Austerity packages announced by the countries are incorporating demand side and supply side policies to reduce the fiscal burden of which healthcare costs command a major proportion.

The governmental demand side policies include measures that affect the reimbursements of drugs such as positive and negative lists, cost sharing, reference pricing, risk-sharing contracts, tenders, pay-back arrangements and other provisions aimed at a more rational use of pharmaceutical products and making demand more price sensitive. The most applied supply policy is price regulation which includes price control and price negotiation. The specific features of individual policies vary significantly across the member states. Single pricing mechanism is still an issue in the Europe.

For more information, visit

About is the leading provider of global market intelligence products and services. With research reports from more than 720 top consulting and advisory firms, offers instant online access to the world's most extensive database of expert insights on global industries, companies, products, and trends. Moreover,'s Research Specialists have in-depth knowledge of the publishers and the various types of reports in their respective industries and are ready to provide research assistance. For more information, call Veronica Franco at 240-747-3016 or visit

Contact Information

  • Contact:
    Veronica Franco
    Email Contact